$WVE

Tan Aik Na sold $3K of WVE

Tan Aik Na sold 432 shares of Wave Life Sciences, Inc. (WVE) at $6.01 on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tan Aik Na
Published Aug 14, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WVE
Neutral
high confidence
Mentioned
$WVE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WVENeutralLow
01

Why it matters

The disclosed sale is small in dollar terms ($2,596.32) and explicitly under a pre-arranged 10b5-1 plan, which generally limits interpretive weight for near-term trading decisions.

02

Market read

Traders may note the planned insider selling, but there is no accompanying fundamental update in the text.

03

What to watch

The article does not disclose any change in business outlook, guidance, or material corporate events, so the signal-to-noise is low.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-13 after-hours; transaction dated 2026-08-11

Background

This is an SEC Form 4 insider transaction disclosure for Wave Life Sciences, reported by a director.

Company-level read

Ticker impact

$WVENeutralHigh confidence
Context

Wave Life Sciences director Tan Aik Na sold 432 shares at $6.01 under a pre-arranged 10b5-1 plan, per a fresh Form 4 filing.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a standard open-market sale coded as S and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a small, planned insider sale.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal risk management or liquidity needs, so traders may still watch for follow-on insider activity.

Key entities

  • Wave Life Sciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tan Aik Na

    Director who sold 432 shares at $6.0100/share under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WVEMedAI 8/10

Wave Life Sciences Ltd.: Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Wave Life Sciences (WVE) initiated a Phase 2a trial for WVE-007, its investigational GalNAc-siRNA, in combination with tirzepatide for obesity treatment. The trial aims to evaluate the combination therapy's efficacy in adults with obesity and type 2 diabetes. Wave also plans to initiate a maintenance trial for WVE-007 in the second half of 2026. Preclinical data suggest WVE-007 could enhance fat loss and preserve muscle when combined with GLP-1 therapies.

$WVEMed

Wave Life Sciences Ltd. (WVE): Results of Operations and Financial Condition

Wave Life Sciences Ltd. (WVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; tri